Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

94.92 +3.70 (+4.06%)
Streaming Delayed Price Updated: 3:43 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,804,862
Open 92.49
Bid (Size) 94.92 (300)
Ask (Size) 94.93 (200)
Prev. Close 91.22
Today's Range 92.46 - 95.27
52wk Range 61.24 - 94.02
Shares Outstanding N/A
Dividend Yield 1.09%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Momentum in Healthcare and Banking to Persist in 2026 as AstraZeneca and Citigroup Lead the Charge
As the global markets open for the first week of 2026, a clear narrative has emerged: the "recovery plays" of 2025 have officially transformed into the "expansion leaders" of the new year. Following a... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls
Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s... 
Via MarketMinute
Topics Economy Intellectual Property World Trade

Performance

YTD
+3.6%
+3.6%
1 Month
+4.0%
+4.0%
3 Month
+11.0%
+11.0%
6 Month
+36.3%
+36.3%
1 Year
+42.0%
+42.0%

More News

Read More
News headline image
Is IonQ Stock a Buy Now? ↗
Via The Motley Fool
News headline image
The Motley Fool Interviews MichaelAaron Flicker: Hacking the Human Mind ↗
Via The Motley Fool
News headline image
AstraZeneca (NASDAQ:AZN) Shows Strong Technical Setup for Potential Breakout ↗
Via Chartmill
News headline image
The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth
Via PredictStreet
Topics Economy Intellectual Property
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer
From AstraZeneca
Via Business Wire
News headline image
Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗
Via Stocktwits
Topics Government World Trade
News headline image
3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now ↗
Via The Motley Fool
News headline image
Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗
Via Stocktwits
Topics Government World Trade
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
From AstraZeneca
Via Business Wire
News headline image
What to Watch With IonQ Stock in 2026 ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH
From AstraZeneca
Via Business Wire
News headline image
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
From AstraZeneca
Via Business Wire
News headline image
US-UK Near Landmark Zero-Tariffs Pharma Deal, Announcement Expected Soon: Report ↗
Via Stocktwits
Topics World Trade
News headline image
Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared ↗
Via Stocktwits
Topics ETFs
News headline image
Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗
Via Investor's Business Daily
Topics Economy Government
News headline image
IMFINZI® approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca PLC-SPONS ADR (NASDAQ:AZN) Passes Key Quality Investing Screen for Long-Term Growth ↗
Via Chartmill
News headline image
Why AstraZeneca Stock Bumped Higher Today ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth
From AstraZeneca
Via Business Wire
News headline image
FDA Approval Delivers Momentum For AstraZeneca's Rare Disease Portfolio ↗
Via Benzinga
News headline image
Where Will IonQ Be in 10 Years? ↗
Via The Motley Fool
News headline image
Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment ↗
Via Investor's Business Daily
News headline image
IonQ (IONQ) Surges on Strong Revenue Outlook and Insider Confidence Amidst Quantum Computing Race
Via MarketMinute
Topics Intellectual Property

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?
Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.
What exchange does AstraZeneca PLC - American Depositary Shares trade on?
AstraZeneca PLC - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?
The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the Nasdaq Stock Market
What is the current price of AstraZeneca PLC - American Depositary Shares?
The current price of AstraZeneca PLC - American Depositary Shares is 94.92
When was AstraZeneca PLC - American Depositary Shares last traded?
The last trade of AstraZeneca PLC - American Depositary Shares was at 01/06/26 03:43 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.